Intended for healthcare professionals

Investigation

Latest from The BMJ

Feature
Rivaroxaban: can we trust the evidence?
Published 03 February 2016
Feature
India’s “health camps”: the drug rep will see you now
Published 02 December 2015
Feature
General practice commissioning: in whose interests?
Published 11 November 2015
Feature
Attacks on publicly funded trials: what happens when industry does not want to know the answer
Published 01 April 2015
Feature
Why have UK doctors been deterred from prescribing Avastin?
Published 01 April 2015
Feature
Sugar’s web of influence 3: Why the responsibility deal is a “dead duck” for sugar reduction
Published 11 February 2015

Pages

Submit your paper